SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of human polyclonal immunotherapeutic antibodies, or human immunoglobulin G (hIgG), to address immunology disorders. The Company is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Companyâs lead product candidate, SAB-142, is a human anti-thymocyte globulin (ATG) focused on preventing or delaying the progression of T1D. SAB-142 is expected to reduce autoimmune beta cell destruction and delay progression or onset of T1D in patients with Stage III or Stage II T1D. The Companyâs genetic engineering platform produces human, multi-targeted, high-potency immunoglobulins, without the need for human donors or convalescent plasma.
äŒæ¥ã³ãŒãSABS
äŒç€ŸåSAB Biotherapeutics Inc
äžå Žæ¥Jan 12, 2021
æé«çµå¶è²¬ä»»è
ãCEOãReich (Samuel J)
åŸæ¥å¡æ°63
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jan 12
æ¬ç€Ÿæåšå°777 W 41St St
éœåžMIAMI BEACH
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·33140
é»è©±çªå·13058452813
ãŠã§ããµã€ãhttps://www.sab.bio/
äŒæ¥ã³ãŒãSABS
äžå Žæ¥Jan 12, 2021
æé«çµå¶è²¬ä»»è
ãCEOãReich (Samuel J)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã